Who has invested in Alnylam Pharmaceuticals?

Arch are named among the investors backing Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals Funding: $135M Raised, Series A

Alnylam Pharmaceuticals funding overview

Alnylam Pharmaceuticals has raised $135M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in October 2024. The round record for Alnylam Pharmaceuticals runs through 2024; nothing later has been disclosed. Investors on record include Arch.

Alnylam Pharmaceuticals at a glance

Total raised: $135M
Latest round: Series A
Latest round date: October 2024
Notable investors: Arch

Frequently asked about Alnylam Pharmaceuticals funding

How much has Alnylam Pharmaceuticals raised?: Alnylam Pharmaceuticals has raised $135M in total disclosed funding across the rounds on record.
Who has invested in Alnylam Pharmaceuticals?: Arch are named among the investors backing Alnylam Pharmaceuticals.
What was the latest Alnylam Pharmaceuticals funding round?: The most recent disclosed round is a Series A, announced in October 2024.
Where is Alnylam Pharmaceuticals based?: No headquarters location is disclosed for Alnylam Pharmaceuticals.
When did Alnylam Pharmaceuticals last raise?: The last disclosed Alnylam Pharmaceuticals round closed in October 2024 at Series A.

We update the Alnylam Pharmaceuticals record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies and their backers are listed below.

Alnylam Pharmaceuticals Funding: $135M Raised, Series A

Alnylam Pharmaceuticals funding overview

Alnylam Pharmaceuticals at a glance

Frequently asked about Alnylam Pharmaceuticals funding

Companies related to Alnylam Pharmaceuticals (30)

Browse related funding lists (3)